MX2010012856A - Opiorfina para el uso como agente psicoestimulante. - Google Patents

Opiorfina para el uso como agente psicoestimulante.

Info

Publication number
MX2010012856A
MX2010012856A MX2010012856A MX2010012856A MX2010012856A MX 2010012856 A MX2010012856 A MX 2010012856A MX 2010012856 A MX2010012856 A MX 2010012856A MX 2010012856 A MX2010012856 A MX 2010012856A MX 2010012856 A MX2010012856 A MX 2010012856A
Authority
MX
Mexico
Prior art keywords
disorder
opiorphin
hyperactivity
deficit
attention
Prior art date
Application number
MX2010012856A
Other languages
English (en)
Inventor
Rougeot Catherine
Original Assignee
Inst Pasteur Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Pasteur Star filed Critical Inst Pasteur Star
Publication of MX2010012856A publication Critical patent/MX2010012856A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a péptidos derivados de la Proteína Lagrimal, Básica, rica en Prolina humana (BPLP), notablemente opiorfina, para el uso como agentes psicoestimulantes. Estos péptidos son útiles en el tratamiento o prevención de enfermedades tales como trastorno obsesivo-compulsivo (OCD), narcolepsia, hipersomnia, descenso de vigilia, trastorno de déficit de atención/hiperactividad (ADHD), déficit de atención y/o hiperactividad en adultos y en niños, depresión, enfermedad bipolar, trastorno distímico y trastorno ciclotímico.
MX2010012856A 2008-05-26 2009-05-26 Opiorfina para el uso como agente psicoestimulante. MX2010012856A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0853400A FR2931362B1 (fr) 2008-05-26 2008-05-26 L'opiorphine pour une utilisation en tant que psychostimulant.
PCT/EP2009/056390 WO2009150040A2 (en) 2008-05-26 2009-05-26 Opiorphin for use as a psychostimulant agent

Publications (1)

Publication Number Publication Date
MX2010012856A true MX2010012856A (es) 2011-03-15

Family

ID=40301816

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012856A MX2010012856A (es) 2008-05-26 2009-05-26 Opiorfina para el uso como agente psicoestimulante.

Country Status (13)

Country Link
US (2) US20110178021A1 (es)
EP (4) EP2307039A2 (es)
JP (2) JP2011521002A (es)
KR (1) KR20110020857A (es)
CN (1) CN102123725A (es)
AU (1) AU2009256765B2 (es)
BR (1) BRPI0909592A2 (es)
CA (1) CA2725243C (es)
FR (1) FR2931362B1 (es)
IL (1) IL209462A (es)
MX (1) MX2010012856A (es)
RU (1) RU2526819C2 (es)
WO (1) WO2009150040A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1577320E (pt) 2004-03-19 2012-10-30 Pasteur Institut Péptidos derivados da proteína bplp humana, polinucleótidos que codificam para os referidos péptidos e anticorpos dirigidos contra os referidos péptidos
PT2274321T (pt) 2008-04-07 2019-03-21 Pasteur Institut Derivados do péptido opiorfina como inibidores potentes da encefalina ¿ degradação de ectopeptidades
US9935633B2 (en) 2015-06-30 2018-04-03 Semiconductor Energy Laboratory Co., Ltd. Logic circuit, semiconductor device, electronic component, and electronic device
CN108250290B (zh) * 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途
EP3781264A4 (en) * 2018-05-18 2021-06-16 Ovid Therapeutics Inc. METHODS FOR TREATING A HYPERACTIVITY DISORDER WITH ATTENTION DEFICIT

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2637600B1 (fr) 1988-10-11 1992-03-06 Pasteur Institut Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
ES2315753T3 (es) * 1999-06-23 2009-04-01 Institut Pasteur Composiciones para el tratamiento de problemas de relaciones interpersonales y trastornos del comportamiento.
PT1216707E (pt) * 2000-12-22 2005-06-30 Pasteur Institut Novas utilizacoes terapeuticas para um smr-1-peptideo
PT1577320E (pt) * 2004-03-19 2012-10-30 Pasteur Institut Péptidos derivados da proteína bplp humana, polinucleótidos que codificam para os referidos péptidos e anticorpos dirigidos contra os referidos péptidos
WO2009090265A1 (en) * 2008-01-18 2009-07-23 Institut Pasteur Method for identifying bplp and opiorphin agonists or antagonists
PT2274321T (pt) * 2008-04-07 2019-03-21 Pasteur Institut Derivados do péptido opiorfina como inibidores potentes da encefalina ¿ degradação de ectopeptidades

Also Published As

Publication number Publication date
CN102123725A (zh) 2011-07-13
AU2009256765A1 (en) 2009-12-17
RU2526819C2 (ru) 2014-08-27
EP3804744A1 (en) 2021-04-14
KR20110020857A (ko) 2011-03-03
CA2725243C (en) 2020-03-10
JP2015131810A (ja) 2015-07-23
WO2009150040A2 (en) 2009-12-17
US20110178021A1 (en) 2011-07-21
RU2010153244A (ru) 2012-07-10
BRPI0909592A2 (pt) 2015-12-01
EP4218786A3 (en) 2023-08-16
JP2011521002A (ja) 2011-07-21
EP2307039A2 (en) 2011-04-13
IL209462A (en) 2017-08-31
WO2009150040A3 (en) 2010-04-15
EP3009142A1 (en) 2016-04-20
AU2009256765B2 (en) 2015-04-16
CA2725243A1 (en) 2009-12-17
FR2931362A1 (fr) 2009-11-27
EP4218786A2 (en) 2023-08-02
US20150329608A1 (en) 2015-11-19
IL209462A0 (en) 2011-01-31
FR2931362B1 (fr) 2017-08-18

Similar Documents

Publication Publication Date Title
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1126007T1 (el) Προαγωγεις αποπτωσης
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
EA200701995A1 (ru) Способы уменьшения кальцификации
ATE548049T1 (de) Verwendung von ides proteinase (von s. pyogenes) zur behandlung von autoimmunkrankheiten und transplantatabstossung
MX2010012856A (es) Opiorfina para el uso como agente psicoestimulante.
MY158932A (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CY1112790T1 (el) Χρηση μαγιας σεληνιου στην αντιμετωπιση της νοσου αλτσχαιμερ
GB0710529D0 (en) Vaccine
EA201001322A1 (ru) Вакцины против хламидиоза
TW200626232A (en) Use of titanium dioxide mixtures for producing catalysts
DE602005012276D1 (de) Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
WO2009013543A3 (en) Targeted binging agents directed to kdr and uses thereof - 035
CO6470824A2 (es) Inmunoglobulinas de dominio variable dual y usos de las mismas
WO2011065982A3 (en) Polymorphisms associated with parkinson's disease
DE602005014463D1 (de) Vielzweckverfahren zur herstellung von elastischen laminaten
WO2009130198A3 (en) Hyperglycosylated human coagulation factor ix
TR201907261T4 (tr) DKK-1 antikorları.
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
CY1112620T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πεπτιδια βασικης πρωτεϊνης της μυελινης και ιατρικες χρησεις αυτων
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
MY155340A (en) Use of cathepsin c
ATE410443T1 (de) Heterocyclyl-substituierte nonadepsipeptide
ATE455789T1 (de) Substituierte nonadepsipeptide

Legal Events

Date Code Title Description
FC Refusal